Literature DB >> 2680911

Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection.

S Pelkonen1, G Pluschke.   

Abstract

Functional properties of rat immunoglobulins obtained from hybridoma isotype switch variants were studied in vivo in a rat model for neonatal bacterial sepsis. Escherichia coli 018:K1, a common cause of human neonatal sepsis and meningitis, was injected intravenously into 6-day-old rats after incubation with 018-specific antibodies IgM, IgG1, IgG2a, IgG2b, IgG2c, IgE and IgA. The clearance of bacteria treated with saline or IgE was low, whereas monoclonal antibodies of other isotypes triggered hepatic sequestration and killing of the K1 E. coli cells. All four IgG subclasses were more efficient than IgM and IgA. Comparable results were obtained upon injecting antibodies into rats with an established fulminating bacteraemia. IgM was inactive in animals depleted of complement with cobra-venom factor (CVF), whereas IgG2b was able to trigger hepatic clearance independently of complement.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680911      PMCID: PMC1385427     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Role of immunity in the clearance of bacteremia due to Haemophilus influenzae.

Authors:  P F Weller; A L Smith; D H Smith; P Anderson
Journal:  J Infect Dis       Date:  1978-10       Impact factor: 5.226

2.  Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1.

Authors:  M P Glode; A Sutton; E R Moxon; J B Robbins
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity.

Authors:  A Nicholson; I H Lepow
Journal:  Science       Date:  1979-07-20       Impact factor: 47.728

4.  A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia.

Authors:  E J Brown; S W Hosea; C H Hammer; C G Burch; M M Frank
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

5.  Dynamics of Escherichia coli infection and meningitis in infant rats.

Authors:  R Bortolussi; P Ferrieri; L W Wannamaker
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

6.  The protective capacity of immune sera in experimental mouse salmonellosis is mainly due to IgM antibodies.

Authors:  H Saxen; O Mäkelä
Journal:  Immunol Lett       Date:  1982-11       Impact factor: 3.685

7.  Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen.

Authors:  R Bortolussi; P Ferrier
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

8.  Epidemiology of Escherichia coli K1 in healthy and diseased newborns.

Authors:  L D Sarff; G H McCracken; M S Schiffer; M P Glode; J B Robbins; I Orskov; F Orskov
Journal:  Lancet       Date:  1975-05-17       Impact factor: 79.321

9.  Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.

Authors:  A S Cross; W Zollinger; R Mandrell; P Gemski; J Sadoff
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  Six widespread bacterial clones among Escherichia coli K1 isolates.

Authors:  M Achtman; A Mercer; B Kusecek; A Pohl; M Heuzenroeder; W Aaronson; A Sutton; R P Silver
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

View more
  4 in total

1.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

2.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

4.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.